- Report
- April 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- May 2025
- 190 Pages
Global
From €3211EUR$3,545USD£2,768GBP
€3568EUR$3,939USD£3,076GBP
- Report
- May 2025
- 195 Pages
Global
From €3211EUR$3,545USD£2,768GBP
€3568EUR$3,939USD£3,076GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €2718EUR$3,000USD£2,343GBP
- Clinical Trials
- April 2025
- 450 Pages
Global
From €4529EUR$5,000USD£3,904GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4529EUR$5,000USD£3,904GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1132EUR$1,250USD£976GBP
- Report
- May 2025
- 110 Pages
Global
From €4303EUR$4,750USD£3,709GBP
- Report
- June 2025
- 180 Pages
Global
From €2537EUR$2,800USD£2,186GBP
€3624EUR$4,000USD£3,123GBP
- Report
- July 2022
- 263 Pages
Global
From €1800EUR$2,129USD£1,606GBP
- Report
- July 2022
- 60 Pages
Global
From €600EUR$710USD£535GBP
- Report
- November 2021
- 222 Pages
Global
From €2446EUR$2,700USD£2,108GBP
€2718EUR$3,000USD£2,343GBP
- Report
- July 2022
- 165 Pages
Global
From €5390EUR$5,950USD£4,646GBP
- Report
- March 2024
- 200 Pages
Global
From €3759EUR$4,150USD£3,240GBP
- Report
- July 2023
- 145 Pages
Global
From €2854EUR$3,150USD£2,460GBP
- Report
- October 2024
- 87 Pages
Spain
From €2695EUR$2,975USD£2,323GBP
€3171EUR$3,500USD£2,733GBP
- Report
- June 2024
- 182 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Report
- November 2023
- 90 Pages
France
From €2695EUR$2,975USD£2,323GBP
€3171EUR$3,500USD£2,733GBP
- Report
- November 2023
- 81 Pages
Germany
From €2695EUR$2,975USD£2,323GBP
€3171EUR$3,500USD£2,733GBP
- Report
- October 2023
- 81 Pages
Japan
From €2695EUR$2,975USD£2,323GBP
€3171EUR$3,500USD£2,733GBP

The B Cell Maturation Antigen (BCMA) market is a subset of the oncology drugs market. BCMA is a protein found on the surface of B cells, a type of white blood cell. BCMA is a promising target for cancer immunotherapy, as it is expressed on multiple myeloma cells and other B-cell malignancies. BCMA-targeted therapies are designed to stimulate the body's immune system to recognize and attack cancer cells.
BCMA-targeted therapies are being developed by a number of companies, including Amgen, Bristol-Myers Squibb, Celgene, Gilead Sciences, and Novartis. These companies are researching and developing BCMA-targeted therapies for multiple myeloma and other B-cell malignancies. Additionally, several clinical trials are underway to evaluate the safety and efficacy of BCMA-targeted therapies. Show Less Read more